Orbimed Advisors LLC Xencor Inc Transaction History

Orbimed Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$20.08 - $25.39 $384,371 - $486,015	19,142 New	19,142 $385,000
Q2 2018 Aug 14, 2018	SELL	$28.41 - $42.41 $17.4 Million - $26 Million	-612,500 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$21.18 - $33.78 $8.68 Million - $13.8 Million	-409,600 Reduced 40.07%	612,500 $18.4 Million
Q4 2017 Feb 14, 2018	BUY	$19.29 - $24.83 $5.3 Million - $6.82 Million	274,856 Added 36.78%	1,022,100 $22.4 Million
Q3 2017 Nov 14, 2017	BUY	$19.61 - $23.35 $14.7 Million - $17.4 Million	747,244	747,244 $17.1 Million

215

71.5M

2.5K

7.9K

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.42B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.